Company Description
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women’s health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders.
It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Shawn Singh |
Contact Details
Address: 343 Allerton Avenue South San Francisco, California 94080 United States | |
| Phone | 650 577 3600 |
| Website | vistagen.com |
Stock Details
| Ticker Symbol | VTGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001411685 |
| CUSIP Number | 92840H202 |
| ISIN Number | US92840H4002 |
| Employer ID | 20-5093315 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shawn K. Singh J.D. | President, Chief Executive Officer and Director |
| Trisha Fitzmaurice | Senior Vice President of Human Resources |
| Dr. Allen Easley Cato III, M.D., Ph.D. | Senior Vice President of Integrated Drug Development |
| Dr. Mark J. Ginski Ph.D. | Senior Vice President and Head of Chemistry, Manufacturing and Controls |
| Dr. Louis Monti M.D., Ph.D. | Senior Vice President of Translational Neuroscience |
| Dr. Azmi Nasser BPHARM, Ph.D. | Senior Vice President of Clinical Research and Development |
| Dr. Angel S. Angelov M.B.A., M.D. | Chief Medical Officer |
| Jessica R. Haskell J.D. | Vice President, Associate General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | 8-K | Current Report |
| Jun 15, 2026 | 10-K | Annual Report |
| Jun 15, 2026 | 8-K | Current Report |
| Jun 9, 2026 | 8-K | Current Report |
| May 19, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 8-K | Current Report |
| May 8, 2026 | 8-K | Current Report |
| Apr 28, 2026 | 8-K | Current Report |
| Apr 13, 2026 | 8-K | Current Report |